Alloy Women’s Health, a menopause care platform offering telemedicine services and treatment plans, has secured $16 million in Series A funding. The round was led by Kairos HQ, with participation from PACE Healthcare Capital, Emmeline Ventures, and Amboy Street Ventures.
The funding announcement comes as Alloy marks its three-year anniversary and achievement of profitability, with the company reporting 300% year-over-year growth in its customer base. The platform has helped “tens of thousands of women across the United States find relief from perimenopause and menopause symptoms,” according to the company’s recent LinkedIn announcement.
The funding comes at a crucial time in women’s health. According to Alloy’s data, approximately 1.3 million women enter menopause each year in the United States, yet less than 2% receive adequate treatment and care. The company notes that many women wait over three years before seeking relief for their symptoms.
“When we first spoke to investors, the response we often heard was, ‘That’s kind of niche, isn’t it?'” co-founder Anne Fulenwider told Fortune. However, the landscape has shifted significantly, with investors now recognizing the potential of the menopause care market, estimated at $17 billion globally.
Alloy operates on a direct-to-consumer model, charging a $50 annual fee with prescriptions starting at $40 per month. The company has chosen not to accept insurance, focusing instead on price transparency and accessibility. The platform currently employs 28 full-time staff members and works with approximately two dozen doctors.
The new funding will enable Alloy to expand beyond treating acute menopause symptoms to offering products across hair, skin, and sexual wellness categories for women in midlife. The company has already shown innovation in this space, recently releasing results from an independent, double-blind study on their M4 Estriol Face Cream, which demonstrated significant improvements in skin appearance and health.
“No woman should ever have to wait to feel her best during perimenopause, menopause and beyond,” stated co-founders Anne Fulenwider and Monica Molenaar in their LinkedIn announcement. “We’re proud to be at the forefront of this conversation, because there’s too much at stake to stay silent.”
